Selected Start-Ups (12/00)
In Vivo summarizes the technologies of several recently founded companies: Roche has funneled its IP in antibiotics, antifungals and dermatology into spin-off Basilea Pharmaceutica. Building on technology invented by NASA to detect life on Mars, BioLuminate Inc. will develop a diagnostic probe to measure breast cancer indicators after initial screening has revealed a region of concern. Integrative Proteomics Inc. aims to be a dominant player in proteomics with its platform for high-throughput protein expression and purification, protein-protein interaction and 3-dimensional structure determination. invivodata inc. is offering a money-back guarantee to users of its invivosystem, a handheld method for recording, managing and analyzing real-time patient experience data during pharmaceutical clinical trials. Metazoa Systems Inc. has launched a web portal offering research management tools for life science researchers. Aventis CropScience spin-off Scynexis Chemistry & Automation Inc. will provide drug discovery chemistry services for pharmaceutical and other life sciences clients.
You may also be interested in...
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.